FDA Off-Label Use Concerns Focus On Biliary Stents, Mapping Catheters
This article was originally published in The Gray Sheet
Executive Summary
Biliary stents and diagnostic mapping catheters comprise the majority of devices deemed by FDA's Office of Device Evaluation to possess a "reasonable likelihood" that they will be used for an off-label use that "could cause harm."